Product Description
Mechanisms of Action: FAP Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location: Europe
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Colorectal Cancer
Phase 1: Non-Small-Cell Lung Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02209727 |
NCT02209727 | P1 |
Terminated |
Non-Small-Cell Lung Cancer |
2002-06-01 |
2019-03-20 |
Treatments |
|
NCT02198274 |
NCT02198274 | P2 |
Completed |
Colorectal Cancer |
2000-10-01 |
2019-03-20 |
Treatments |